Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Date: April 24, 2020
Context: The registrant, a biopharmaceutical company focused on regenerative cell therapy, reported the approval of a significant non-dilutive financing from the European Investment Bank (EIB) and updated risk factors regarding the impact of the COVID-19 pandemic on its operations and clinical trials.
Key Financial Metrics and Capital Structure
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The primary financial disclosure relates to a new financing arrangement:
- Financing Amount: Approved €50 million non-dilutive financing from the EIB.
- Structure: Deployed in three tranches; the first tranche is €20 million.
- Interest Rate: Between 3% and 4% per tranche.
- Repayment Terms: Unsecured; payable in lump sums 5 years after disbursement of the first and second tranches. The third tranche is payable in two annual installments starting 4 years after disbursement.
- Royalties: EIB entitled to royalties on future revenues for seven years starting in 2024, ranging from 0.2% to 2.3%, pro-rated to disbursed amounts.
- Usage of Funds: Supports up to 50% of R&D project costs in the EU, specifically advancing the PLX cells platform and clinical development for COVID-19 complications.
Material Changes and Operational Updates
Financing Milestone: The EIB approved the financing on April 24, 2020. The definitive agreement is expected to be signed on April 30, 2020, though execution is not guaranteed.
Clinical Development (COVID-19):
- Compassionate Use: Preliminary data reported on April 7, 2020, after treating seven patients in Israel with acute respiratory failure. On April 13, 2020, the first patient in the U.S. was treated under the FDA's Single Patient Expanded Access Program.
- Future Trials: The company intends to apply for a multinational regulated clinical trial program for PLX cells to treat COVID-19 complications.
Operational Impact of Pandemic:
- Offices remain open in compliance with Israeli rules, though remote work capacity has been increased.
- Potential disruptions to clinical trial enrollment and FDA review processes due to the pandemic.
- No disruptions to raw material supply reported to date.
Guidance, Risks, and Contingencies
Forward-Looking Statements: Management believes the financing will accelerate the path to approval for the multinational COVID-19 clinical trial. However, there is no guarantee the definitive agreement will be executed or that milestones for subsequent tranches will be met.
Material Risks:
- Pandemic Impact: The COVID-19 pandemic may materially and adversely affect business operations, clinical trial conduct, and global economies.
- Regulatory Delays: Potential delays in FDA and other health authority reviews due to resource constraints.
- Product Efficacy: PLX cells may not be successful in treating COVID-19 complications.
- Market Volatility: Stock price has fluctuated significantly during the outbreak.
- Liquidity: The ultimate impact of the pandemic on liquidity and capital resources remains uncertain.
Investor Verification Checklist
- Confirm the execution of the definitive financing agreement with the EIB on or after April 30, 2020.
- Monitor the achievement of clinical and regulatory milestones required to release the remaining tranches of the €50 million financing.
- Track the status of the multinational clinical trial application for PLX cells regarding COVID-19.
- Assess the actual impact of the pandemic on the enrollment rates of ongoing Phase III trials for critical limb ischemia and hip fracture recovery.
- Review future filings for updates on the royalty obligations (0.2% to 2.3%) and their potential impact on future revenue streams.